Top

Published in:

Open Access 01-01-2019 | General Gynecology

Incidence and groups at risk for unexpected uterine leiomyosarcoma: a Dutch nationwide cohort study

Authors: Lukas van den Haak, Cor. D. de Kroon, Milo. I. Warmerdam, Albert G. Siebers, Johann P. Rhemrev, Theodoor. E. Nieboer, Frank Willem Jansen

Published in: Archives of Gynecology and Obstetrics | Issue 1/2019

Abstract

Objective

To estimate the risk of uterine leiomyosarcoma in patients undergoing gynecological surgery and also to identify groups at risk for unrecognized uterine leiomyosarcoma.

Methods

A national cohort study was performed evaluating all uterine leiomyosarcoma (ULMS) diagnosed in The Netherlands between January 2000 and September 2015. Cases were identified and supplied by the nationwide network and registry of histo- and cytopathology in The Netherlands (PALGA). Unexpected and expected ULMS were compared. Approval for this study was granted by the Medical Ethics Committee of all participating hospitals and by the review board of PALGA.

Results

262 original cases were included. The overall incidence of ULMS in our study was 0.25% or 1:400 patients. The incidence of unexpected ULMS was 0.12% or 1:865 patients. Preoperatively, a malignancy was unexpected in 46% of the cases and expected in 54%. Abnormal uterine bleeding constituted most of the symptoms. 90% of women underwent abdominal hysterectomy and/or bilateral salpingo-oophorectomy.

Conclusions

Leiomyosarcoma are rare. Women aged 40–50 years with abnormal uterine bleeding are most at risk for unexpected ULMS. In contrast, this risk is low in postmenopausal women. ULMS were highly uncommon in women aged under 40 years.

Stentz NC, Cooney LG, Sammel M et al (2017) Changes in myomectomy practice after the U.S. Food and Drug Administration Safety Communication on power morcellation. Obstet Gynecol 129(6):1007–1013CrossRef

Singh SS, Bougie O, Arendas K et al (2015) Morcellation in anada: perspectives on current practices and future implications. J Minim Invasive Gynecol 22(7):1142–1144CrossRef

Lum DA, Sokol ER, Berek JS et al (2016) Impact of the 2014 Food and Drug Administration warnings against power morcellation. J Minim Invasive Gynecol 23(4):548–556CrossRef

Mandato VD, Torricelli F, Pirillo D et al (2016) Impact of the Food and Drug Administration Safety Communication on the use of power morcellator in daily clinical practice: an Italian survey. J Minim Invasive Gynecol 23(2):206–214CrossRef

Saadat S, Arden D (2017) How has the FDA morcellation warning affected rates of minimally invasive hysterectomy?[30G]. Obstet Gynecol 129:79SCrossRef

U.S. Food and Drug Administration. Laparoscopic Uterine Power Morcellation in Hysterectomy and Myomectomy: FDA Safety Communication. https://www.fda.gov/medicaldevices/productsandmedicalprocedures/surgeryandlifesupport/ucm584463.htm. Accessed 6 Jul 2017

Hodgson B (2014) AAGL practice report: morcellation during uterine tissue extraction. J Minim Invasive Gynecol 21(4):517–530CrossRef

Brolmann H, Tanos V, Grimbizis G et al (2015) Options on fibroid morcellation: a literature review. Gynecol Surg 12(1):3–15CrossRef

Siedhoff MT, Doll KM, Clarke-Pearson DL, Rutstein SE (2017) Laparoscopic hysterectomy with morcellation vs abdominal hysterectomy for presumed fibroids: an updated decision analysis following the 2014 Food and Drug Administration safety communications. Am J Obstet Gynecol 216(3):259CrossRef

10.

FDA updated assessment of the use of laparoscopic power morcellators to treat uterine fibroids December 2017. https://www.fda.gov/downloads/medicaldevices/productsandmedicalprocedures/surgeryandlifesupport/ucm584539.pdf. Accessed 17 Jan 17, 2018

11.

Casparie M, Tiebosch AT, Burger G et al (2007) Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol 29(1):19–24PubMedPubMedCentral

12.

Skorstad M, Kent A, Lieng M (2016) Uterine leiomyosarcoma—incidence, treatment, and the impact of morcellation. A nationwide cohort study. Acta Obstet Gynecol Scand 95(9):984–990CrossRef

13.

Oduyebo T, Hinchcliff E, Meserve EE et al (2016) Risk factors for occult uterine sarcoma among women undergoing minimally invasive gynecologic surgery. J Minim Invasive Gynecol 23(1):34–39CrossRef

14.

Rodriguez AM, Asoglu MR, Sak ME et al (2016) Incidence of occult leiomyosarcoma in presumed morcellation cases: a database study. Eur J Obstet Gynecol Reprod Biol 197:31–35CrossRef

15.

Raine-Bennett T, Tucker LY, Zaritsky E et al (2016) Occult uterine sarcoma and leiomyosarcoma: incidence of and survival associated with morcellation. Obstet Gynecol 127(1):29–39CrossRef

16.

Raspagliesi F, Maltese G, Bogani G et al (2017) Morcellation worsens survival outcomes in patients with undiagnosed uterine leiomyosarcomas: a retrospective MITO group study. Gynecol Oncol 144(1):90–95CrossRef

17.

Parker WH, Fu YS, Berek JS (1994) Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstet Gynecol 83(3):414–418PubMed

18.

Nugent W, Engelke G, Reicke S et al (2015) Laparoscopic supracervical hysterectomy or myomectomy with power morcellation: risk of uterine leiomyosarcomas. A retrospective trial including 35.161 women in Germany. J Minim Invasive Gynecol 22(S6):S2–S3CrossRef

19.

Maresh MJ, Metcalfe MA, McPherson K et al (2002) The VALUE national hysterectomy study: description of the patients and their surgery. BJOG 109(3):302–312CrossRef

20.

Exacoustos C, Romanini ME, Amadio A et al (2007) Can gray-scale and color Doppler sonography differentiate between uterine leiomyosarcoma and leiomyoma? J Clin Ultrasound 35(8):449–457CrossRef

Title: Incidence and groups at risk for unexpected uterine leiomyosarcoma: a Dutch nationwide cohort study
Authors: Lukas van den Haak
Cor. D. de Kroon
Milo. I. Warmerdam
Albert G. Siebers
Johann P. Rhemrev
Theodoor. E. Nieboer
Frank Willem Jansen
Publication date: 01-01-2019
Publisher: Springer Berlin Heidelberg
Published in: Archives of Gynecology and Obstetrics / Issue 1/2019
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-018-4949-4

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Incidence and groups at risk for unexpected uterine leiomyosarcoma: a Dutch nationwide cohort study

Abstract

Objective

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2019

Association of maternal iron deficiency anemia with the risk of gestational diabetes mellitus: a meta-analysis

Adherence to gynecological screening impacted by experienced orthodontic treatment in childhood

Risk factors of persistent HPV infection after treatment for high-grade squamous intraepithelial lesion

Malignant transformation of adenomyosis: literature review and meta-analysis

Oxytocin infusion reduces bleeding during abdominal myomectomies: a randomized controlled trial

Five cases of uterine perivascular epithelioid cell tumors (PEComas) and review of literature